
# SAFETY DATA SHEET





# SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

**Product name** : INERTA 50 VARNISH

1.2 Relevant identified uses of the substance or mixture and uses advised against

**Product use** : Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

responsible for this SDS

**National contact** 

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

1.4 Emergency telephone number

**National advisory body/Poison Centre** 

: Malta Competition and Consumer Affairs Authority (MCCAA): +356 2395 2000 Telephone number

## **SECTION 2: Hazards identification**

## 2.1 Classification of the substance or mixture

**Product definition** : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1, H317 Carc. 2, H351 **STOT SE 3, H335 STOT SE 3, H336** 

**STOT RE 2, H373** 

Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

### 2.2 Label elements

**Hazard pictograms** 









Signal word : Danger

**Hazard statements** : H226 - Flammable liquid and vapour.

H315 - Causes skin irritation.

H317 - May cause an allergic skin reaction.

H318 - Causes serious eye damage.

H335 - May cause respiratory irritation.

H336 - May cause drowsiness or dizziness.

H351 - Suspected of causing cancer.

Date of issue/Date of revision : 10/08/2022 Date of previous issue 1/20 Version :1 : No previous validation **INERTA 50 VARNISH Label No: 38447** 

# **SECTION 2: Hazards identification**

H373 - May cause damage to organs through prolonged or repeated exposure.

H412 - Harmful to aquatic life with long lasting effects.

#### **Precautionary statements**

**Prevention** 

: P280 - Wear protective gloves, protective clothing, eye protection, face protection,

or hearing protection.

P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition

sources. No smoking.

P260 - Do not breathe vapour.

Response : P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes.

Remove contact lenses, if present and easy to do. Continue rinsing.

Storage : P403 + P233 - Store in a well-ventilated place. Keep container tightly closed.

Disposal : P501 - Dispose of contents and container in accordance with all local, regional,

national and international regulations.

**Hazardous ingredients** : Phenol, 4,4'-(1-methylethylidene)bis-, polymer with 2,2'-[(1-methylethylidene)bis

(4,1-phenyleneoxymethylene)]bis[oxirane Solvent naphtha (petroleum), light aromatic

iso-butanol Xylene

Supplemental label elements

: Contains epoxy constituents. May produce an allergic reaction.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles : Not applicable.

### 2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII  This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Other hazards which do not result in classification

: None known.

# **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures : Mixture

| Product/ingredient name                                                                                                      | Identifiers                                                                             | %         | Classification                                                                                                        | Specific Conc.<br>Limits, M-factors<br>and ATEs | Type |
|------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------|-----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|------|
| Phenol, 4,4'- (1-methylethylidene)bis-, polymer with 2,2'-[ (1-methylethylidene)bis (4,1-phenyleneoxymethylene)] bis[oxirane | CAS: 25036-25-3                                                                         | ≥25 - ≤50 | Skin Irrit. 2, H315<br>Eye Irrit. 2, H319<br>Skin Sens. 1, H317                                                       | -                                               | [1]  |
| Solvent naphtha<br>(petroleum), light aromatic                                                                               | REACH #:<br>01-2119455851-35<br>EC: 265-199-0<br>CAS: 64742-95-6<br>Index: 649-356-00-4 | ≥10 - <25 | Flam. Liq. 3, H226<br>STOT SE 3, H335<br>STOT SE 3, H336<br>Asp. Tox. 1, H304<br>Aquatic Chronic 2,<br>H411<br>EUH066 | -                                               | [1]  |
| iso-butanol                                                                                                                  | REACH #:<br>01-2119484609-23<br>EC: 201-148-0<br>CAS: 78-83-1<br>Index: 603-108-00-1    | ≥10 - ≤25 | Flam. Liq. 3, H226<br>Skin Irrit. 2, H315<br>Eye Dam. 1, H318<br>STOT SE 3, H335<br>STOT SE 3, H336                   | -                                               | [1]  |

Date of issue/Date of revision: 10/08/2022Date of previous issue: No previous validationVersion: 12/20INERTA 50 VARNISHLabel No :38447

#### SECTION 3: Composition/information on ingredients REACH #: ≥10 - ≤25 Flam. Liq. 3, H226 ATE [Dermal] = **Xylene** [1] [2] 01-2119488216-32 Acute Tox. 4, H312 1100 mg/kg EC: 215-535-7 Acute Tox. 4, H332 ATE [Inhalation CAS: 1330-20-7 Skin Irrit. 2, H315 (vapours)] = 11 mg/ Index: 601-022-00-9 Eye Irrit. 2, H319 **STOT SE 3, H335 STOT RE 2, H373** (oral, inhalation) Asp. Tox. 1, H304 Methylisobutylketone REACH #: ≤10 Flam. Lig. 2, H225 ATE [Inhalation] [1] [2] 01-2119473980-30 Acute Tox. 4, H332 (vapours)] = 11 mg/EC: 203-550-1 Eye Irrit. 2, H319 CAS: 108-10-1 Carc. 2. H351 Index: 606-004-00-4 **STOT SE 3. H336** EUH066 ATE [Inhalation Cyclohexanone REACH #: ≤5 Flam. Liq. 3, H226 [1] [2] Acute Tox. 4, H332 (gases)] = 800001-2119453616-35 EC: 203-631-1 ppm CAS: 108-94-1 Index: 606-010-00-7 Flam. Liq. 3, H226 2-Methoxy-1-methylethyl REACH #: ≤5 [1] [2] STOT SE 3, H336 acetate 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6 Index: 607-195-00-7 Ethylbenzene REACH #: ≤3 Flam. Liq. 2, H225 ATE [Inhalation [1] [2] 01-2119489370-35 Acute Tox. 4, H332 (vapours)] = 11 mg/ EC: 202-849-4 STOT RE 2, H373 CAS: 100-41-4 (hearing organs) (oral, Index: 601-023-00-4 inhalation) Asp. Tox. 1, H304 Urea-formaldehyde-polymer CAS: 68002-18-6 ≤3 Aquatic Chronic 4, [1] H413 Oxirane, mono[ <1 Skin Irrit. 2, H315 [1] REACH #: (C12-14-alkyloxy)methyl] 01-2119485289-22 Skin Sens. 1, H317 derivs. EC: 271-846-8 CAS: 68609-97-2 Index: 603-103-00-4 See Section 16 for

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

### **Type**

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit

### **SECTION 4: First aid measures**

## 4.1 Description of first aid measures

**Eye contact** 

: Get medical attention immediately. Call a poison center or physician. Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Chemical burns must be treated promptly by a physician.

the full text of the H statements declared

above.

Date of issue/Date of revision: 10/08/2022Date of previous issue: No previous validationVersion: 13/20INERTA 50 VARNISHLabel No :38447

# **SECTION 4: First aid measures**

#### Inhalation

: Get medical attention immediately. Call a poison center or physician. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

### **Skin contact**

: Get medical attention immediately. Call a poison center or physician. Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Chemical burns must be treated promptly by a physician. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.

### Ingestion

: Get medical attention immediately. Call a poison center or physician. Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Chemical burns must be treated promptly by a physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

#### **Protection of first-aiders**

No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

# 4.2 Most important symptoms and effects, both acute and delayed

**Over-exposure signs/symptoms** 

**Eye contact** : Adverse symptoms may include the following:

> pain watering redness

Inhalation : Adverse symptoms may include the following:

respiratory tract irritation

coughing

nausea or vomiting

headache

drowsiness/fatigue dizziness/vertigo unconsciousness

Skin contact : Adverse symptoms may include the following:

pain or irritation

redness

blistering may occur

Ingestion : Adverse symptoms may include the following:

stomach pains

## 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : In case of inhalation of decomposition products in a fire, symptoms may be delayed.

The exposed person may need to be kept under medical surveillance for 48 hours.

**Specific treatments** : No specific treatment.

Date of issue/Date of revision : 10/08/2022 Date of previous issue Version :1 4/20 : No previous validation **Label No: 38447** 

# SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing

media

: Use dry chemical, CO2, water spray (fog) or foam.

**Unsuitable extinguishing** 

media

: Do not use water jet.

### 5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture : Flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

**Hazardous combustion** products

: Decomposition products may include the following materials: carbon dioxide

carbon monoxide nitrogen oxides

### 5.3 Advice for firefighters

**Special protective actions** for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.

**Special protective** equipment for fire-fighters Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

# SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Do not breathe vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders:

If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

# 6.2 Environmental precautions

: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

### 6.3 Methods and material for containment and cleaning up

**Small spill** 

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Large spill

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with noncombustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product.

Date of issue/Date of revision : 10/08/2022 Date of previous issue Version:1 5/20 : No previous validation **INERTA 50 VARNISH Label No: 38447** 

# **SECTION 6: Accidental release measures**

### 6.4 Reference to other sections

See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

# SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 7.1 Precautions for safe handling

#### **Protective measures**

: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Avoid exposure - obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not breathe vapour or mist. Do not ingest. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.

# Advice on general occupational hygiene

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

## 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

## **Seveso Directive - Reporting thresholds**

## **Danger criteria**

|     | Notification and MAPP threshold | Safety report threshold |
|-----|---------------------------------|-------------------------|
| P5c | 5000 tonne                      | 50000 tonne             |

### 7.3 Specific end use(s)

Recommendations : Not available. **Industrial sector specific** : Not available. solutions

# **SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

### 8.1 Control parameters

Occupational exposure limits

Date of issue/Date of revision : 10/08/2022 Version :1 6/20 Date of previous issue : No previous validation **Label No: 38447** 

# **SECTION 8: Exposure controls/personal protection**

| Product/ingredient name                   | Exposure limit values                                                                                                    |
|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| Xylene                                    | EU OEL (Europe, 10/2019). [xylene, mixed isomers] Absorbed through skin. Notes: list of indicative occupational exposure |
|                                           | limit values                                                                                                             |
|                                           | TWA: 50 ppm 8 hours.                                                                                                     |
|                                           | TWA: 221 mg/m³ 8 hours.                                                                                                  |
|                                           | STEL: 100 ppm 15 minutes.                                                                                                |
|                                           | STEL: 442 mg/m³ 15 minutes.                                                                                              |
| Methylisobutylketone                      | EU OEL (Europe, 10/2019). Notes: list of indicative                                                                      |
|                                           | occupational exposure limit values                                                                                       |
|                                           | TWA: 20 ppm 8 hours.                                                                                                     |
|                                           | TWA: 83 mg/m³ 8 hours.                                                                                                   |
|                                           | STEL: 50 ppm 15 minutes.                                                                                                 |
|                                           | STEL: 208 mg/m³ 15 minutes.                                                                                              |
| Cyclohexanone                             | EU OEL (Europe, 10/2019). Absorbed through skin. Notes: list                                                             |
|                                           | of indicative occupational exposure limit values                                                                         |
|                                           | TWA: 10 ppm 8 hours.                                                                                                     |
|                                           | TWA: 40.8 mg/m³ 8 hours.                                                                                                 |
|                                           | STEL: 20 ppm 15 minutes.                                                                                                 |
| O Matherina di manthode thod annotate     | STEL: 81.6 mg/m³ 15 minutes.                                                                                             |
| 2-Methoxy-1-methylethyl acetate           | EU OEL (Europe, 10/2019). Absorbed through skin. Notes: list                                                             |
|                                           | of indicative occupational exposure limit values                                                                         |
|                                           | TWA: 50 ppm 8 hours. TWA: 275 mg/m³ 8 hours.                                                                             |
|                                           | STEL: 100 ppm 15 minutes.                                                                                                |
|                                           | STEL: 100 ppm 13 minutes.  STEL: 550 mg/m³ 15 minutes.                                                                   |
| Ethylbenzene                              | EU OEL (Europe, 10/2019). Absorbed through skin. Notes: list                                                             |
| Luiyiberizerie                            | of indicative occupational exposure limit values                                                                         |
|                                           | TWA: 100 ppm 8 hours.                                                                                                    |
|                                           | TWA: 100 ppin 6 hours.                                                                                                   |
|                                           | STEL: 200 ppm 15 minutes.                                                                                                |
|                                           | STEL: 884 mg/m³ 15 minutes.                                                                                              |
| Decomposed of monitoring and this made to | OTEL: 00+ mg/m TO mindeos.                                                                                               |

# Recommended monitoring procedures

: If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

### **DNELs/DMELs**

| NEL      | Long term Inhalation Long term Inhalation | 0.41 mg/m <sup>3</sup><br>1.9 mg/m <sup>3</sup>                                                                   | General<br>population<br>Workers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Systemic                                                                                                                                                                                                                                                                                                                   |
|----------|-------------------------------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|          | Long term                                 | 1.9 mg/m³                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Systemia                                                                                                                                                                                                                                                                                                                   |
|          |                                           | 1.9 mg/m <sup>3</sup>                                                                                             | Workers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Cyatamia                                                                                                                                                                                                                                                                                                                   |
|          | Inhalation                                | =                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Systemic                                                                                                                                                                                                                                                                                                                   |
|          |                                           |                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                                          |
| NEL      | Long term                                 | 178.57 mg/                                                                                                        | General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Local                                                                                                                                                                                                                                                                                                                      |
|          | Inhalation                                | m³                                                                                                                | population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                            |
| NEL      | Short term                                | 640 mg/m <sup>3</sup>                                                                                             | General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Local                                                                                                                                                                                                                                                                                                                      |
|          | Inhalation                                |                                                                                                                   | population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                            |
| NEL      | Long term                                 | 837.5 mg/                                                                                                         | Workers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Local                                                                                                                                                                                                                                                                                                                      |
|          | Inhalation                                | m³                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                            |
| NEL      | Short term                                | 1066.67                                                                                                           | Workers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Local                                                                                                                                                                                                                                                                                                                      |
|          | Inhalation                                | mg/m³                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                            |
| NEL      | Short term                                | 1152 mg/                                                                                                          | General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Systemic                                                                                                                                                                                                                                                                                                                   |
|          | Inhalation                                | m³                                                                                                                | population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                            |
| NEL      | Short term                                | 1286.4 mg/                                                                                                        | Workers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Systemic                                                                                                                                                                                                                                                                                                                   |
| 10<br>10 | NEL<br>NEL                                | NEL Short term Inhalation Long term Inhalation NEL Short term Inhalation NEL Short term Inhalation NEL Inhalation | NEL Short term 1040 mg/m³ lnhalation 1050 kerm | NEL Short term Inhalation NEL Long term B37.5 mg/ Inhalation NEL Short term 1066.67 Morkers Inhalation Morkers NEL Short term Inhalation Morkers |

Date of issue/Date of revision: 10/08/2022Date of previous issue: No previous validationVersion: 17/20INERTA 50 VARNISHLabel No :38447

# SECTION 8: Exposure controls/personal protection

|                                 |        | Inhalation              | m³                     |                    |               |
|---------------------------------|--------|-------------------------|------------------------|--------------------|---------------|
| iso-butanol                     | DNEL   | Long term               | 55 mg/m³               | General            | Local         |
| iso-butarior                    | DINEL  | Inhalation              | 55 mg/m                | population         | Lucai         |
|                                 | DNE    |                         | 210 mg/m3              |                    | Local         |
|                                 | DNEL   | Long term               | 310 mg/m <sup>3</sup>  | Workers            | Local         |
| V 1                             | DAIE   | Inhalation              | 4.0 (1                 | 0 1                |               |
| Xylene                          | DNEL   | Long term Oral          | 1.6 mg/kg              | General            | Systemic      |
|                                 |        |                         | bw/day                 | population         |               |
|                                 | DNEL   | Long term               | 14.8 mg/m³             | General            | Systemic      |
|                                 |        | Inhalation              |                        | population         |               |
|                                 | DNEL   | Long term               | 77 mg/m³               | Workers            | Systemic      |
|                                 |        | Inhalation              |                        |                    |               |
|                                 | DNEL   | Long term Dermal        | 108 mg/kg              | General            | Systemic      |
|                                 |        |                         | bw/day                 | population         |               |
|                                 | DNEL   | Long term Dermal        | 180 mg/kg              | Workers            | Systemic      |
|                                 |        |                         | bw/day                 |                    |               |
|                                 | DNEL   | Short term              | 289 mg/m <sup>3</sup>  | Workers            | Local         |
|                                 |        | Inhalation              |                        |                    |               |
|                                 | DNEL   | Short term              | 289 mg/m <sup>3</sup>  | Workers            | Systemic      |
|                                 |        | Inhalation              | · ·                    |                    |               |
|                                 | DNEL   | Long term               | 65.3 mg/m <sup>3</sup> | General            | Local         |
|                                 |        | Inhalation              | J                      | population         |               |
|                                 | DNEL   | Short term              | 260 mg/m <sup>3</sup>  | General            | Local         |
|                                 |        | Inhalation              | J                      | population         |               |
|                                 | DNEL   | Short term              | 260 mg/m <sup>3</sup>  | General            | Systemic      |
|                                 |        | Inhalation              |                        | population         | -,            |
|                                 | DNEL   | Long term               | 221 mg/m <sup>3</sup>  | Workers            | Local         |
|                                 | D. 122 | Inhalation              | :g/                    | TT GIRGIG          | 2004.         |
| Methylisobutylketone            | DNEL   | Long term Oral          | 4.2 mg/kg              | General            | Systemic      |
| Wellyhoodatymoterio             | DIVLE  | Long tomi oral          | bw/day                 | population         | Cycloniio     |
|                                 | DNEL   | Long term Dermal        | 4.2 mg/kg              | General            | Systemic      |
|                                 | DINLL  | Long term berman        | bw/day                 | population         | Cysternic     |
|                                 | DNEL   | Long term Dermal        | 11.8 mg/               | Workers            | Systemic      |
|                                 | DINLL  | Long term berman        | kg bw/day              | WOIKCIS            | Cysternic     |
|                                 | DNEL   | Long term               | 14.7 mg/m <sup>3</sup> | General            | Local         |
|                                 | DINLL  | Inhalation              | 14.7 mg/m              | population         | Local         |
|                                 | DNEL   |                         | 14.7 mg/m³             | General            | Systemia      |
|                                 | DINEL  | Long term<br>Inhalation | 14.7 mg/m              | population         | Systemic      |
|                                 | DNEL   | Long term               | 02 ma/m³               | Workers            | Local         |
|                                 | DINEL  |                         | 83 mg/m³               | Workers            | Local         |
|                                 | DNE    | Inhalation              | 02 ma/m3               | Morkoro            | Cyatamia      |
|                                 | DNEL   | Long term               | 83 mg/m³               | Workers            | Systemic      |
|                                 | חאבו   | Inhalation              | 455.0/                 | 0                  | Land          |
|                                 | DNEL   | Short term              | 155.2 mg/              | General            | Local         |
|                                 | חאבו   | Inhalation              | m <sup>3</sup>         | population         | 0             |
|                                 | DNEL   | Short term              | 155.2 mg/              | General            | Systemic      |
|                                 | ראבי   | Inhalation              | m <sup>3</sup>         | population         | Local         |
|                                 | DNEL   | Short term              | 208 mg/m <sup>3</sup>  | Workers            | Local         |
|                                 | ראורי  | Inhalation              | 000 / 3                | \\/ = mlc =        | Cuatawa:      |
|                                 | DNEL   | Short term              | 208 mg/m <sup>3</sup>  | Workers            | Systemic      |
| Ovelsk svensky                  | ריי    | Inhalation              | 4 //                   | 0                  | 0             |
| Cyclohexanone                   | DNEL   | Short term Dermal       | 1 mg/kg                | General            | Systemic      |
|                                 | D      |                         | bw/day                 | population         | 0             |
|                                 | DNEL   | Long term Dermal        | 1 mg/kg                | General            | Systemic      |
|                                 | D      | 0 6 .                   | bw/day                 | population         | .             |
|                                 | DNEL   | Short term Oral         | 1.5 mg/kg              | General            | Systemic      |
|                                 |        |                         | bw/day                 | population         |               |
|                                 | DNEL   | Long term Oral          | 1.5 mg/kg              | General            | Systemic      |
|                                 |        |                         | bw/day                 | population         |               |
|                                 | DNEL   | Short term Dermal       | 4 mg/kg                | Workers            | Systemic      |
|                                 |        |                         | bw/day                 |                    |               |
|                                 | DNEL   | Long term Dermal        | 4 mg/kg                | Workers            | Systemic      |
|                                 |        |                         | bw/day                 |                    |               |
|                                 | DNEL   | Long term               | 10 mg/m³               | General            | Systemic      |
|                                 |        | Inhalation              | _                      | population         | -             |
|                                 | DNEL   | Long term               | 20 mg/m³               | General            | Local         |
|                                 |        | Inhalation              |                        | population         |               |
|                                 | DNEL   | Short term              | 20 mg/m³               | General            | Systemic      |
| <br>o of igays/Data of revision | 9/2022 |                         |                        | ious validation Va | roion +1 9/20 |

Date of issue/Date of revision
INERTA 50 VARNISH

: 10/08/2022 Date of previous issue

: No previous validation

**Version** :1 8/20

**Label No** :38447

#### SECTION 8: Exposure controls/personal protection Inhalation population **DNEL** 40 mg/m<sup>3</sup> Short term General Local Inhalation population **DNEL** Long term 40 mg/m<sup>3</sup> Workers Local Inhalation DNEL Long term 40 mg/m<sup>3</sup> Workers Systemic Inhalation **DNEL** 80 mg/m<sup>3</sup> Short term Workers Local Inhalation **DNEL** Short term 80 mg/m<sup>3</sup> Workers Systemic Inhalation Systemic 2-Methoxy-1-methylethyl acetate **DNEL** Long term Oral 1.67 mg/ General kg bw/day population DNEL 33 mg/m<sup>3</sup> Local Long term General Inhalation population **DNEL** Long term 33 mg/m<sup>3</sup> General Systemic Inhalation population **DNEL** Long term Dermal 54.8 mg/ General Systemic kg bw/day population **DNEL** Long term Dermal 153.5 mg/ Workers Systemic kg bw/day 275 mg/m<sup>3</sup> DNEL Long term Workers Systemic Inhalation **DNEL** Short term 550 mg/m<sup>3</sup> Workers Local Inhalation Ethylbenzene DNEL Long term Oral 1.6 mg/kg General Systemic bw/dav population DNEL Long term 15 mg/m<sup>3</sup> General Systemic Inhalation population DNEL Long term 77 mg/m<sup>3</sup> Workers Systemic Inhalation Long term Dermal DNEL 180 mg/kg Workers Systemic bw/day **DNEL** Short term 293 mg/m<sup>3</sup> Workers Local Inhalation **DMEL** Long term 442 mg/m<sup>3</sup> Workers Local Inhalation Short term **DMEL** 884 mg/m<sup>3</sup> Workers Systemic Inhalation Oxirane, mono[(C12-14-alkyloxy) DNEL Long term Oral 0.5 mg/kg General Systemic methyl]derivs. bw/day population **DNEL** Long term Dermal 0.5 mg/kg General Systemic bw/day population 0.87 mg/m<sup>3</sup> **DNEL** Long term General Systemic Inhalation population Long term Dermal **DNEL** 1 mg/kg Workers Systemic bw/day

### **PNECs**

No PNECs available

### 8.2 Exposure controls

**Appropriate engineering** controls

: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.

3.6 mg/m<sup>3</sup>

Workers

Systemic

**Individual protection measures** 

Date of issue/Date of revision : 10/08/2022 Date of previous issue Version :1 9/20 : No previous validation **INERTA 50 VARNISH Label No: 38447** 

**DNEL** 

Long term

Inhalation

# **SECTION 8: Exposure controls/personal protection**

#### **Hygiene measures**

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

### **Eye/face protection**

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles and/or face shield. If inhalation hazards exist, a full-face respirator may be required instead.

# **Skin protection**

**Hand protection** 

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Recommendations: Wear suitable gloves tested to EN374.

< 1 hour (breakthrough time): Nitrile gloves. thickness > 0.3 mm

> 8 hours (breakthrough time): 4H / Silver Shield® gloves.

Wash hands before breaks and immediately after handling the product.

#### **Body protection**

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.

### Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

#### **Respiratory protection**

Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Filter type: A

Filter type (spray application): A P

# **Environmental exposure** controls

Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

# **SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

# 9.1 Information on basic physical and chemical properties

#### **Appearance**

Physical state : Liquid.

Colour : Various

Odour : Slight

Odour threshold : Not available.

Melting point/freezing point : Not available.

boiling range

Initial boiling point and

Date of issue/Date of revision : 10/08/2022 Date of previous issue : No previous validation Version : 1 10/20

INERTA 50 VARNISH Label No :38447

# **SECTION 9: Physical and chemical properties**

| Ingredient name      | °C    | °F    | Method   |
|----------------------|-------|-------|----------|
| iso-butanol          | 108   | 226.4 | OECD 103 |
| Methylisobutylketone | 116.5 | 241.7 |          |

Flammability : Not available.

Lower and upper explosion : Lower: 0.8%

limit : Upper: 7.6%

Flash point : Closed cup: 25°C (77°F)

Auto-ignition temperature

| Ingredient name                             | °C         | °F         | Method    |
|---------------------------------------------|------------|------------|-----------|
| Solvent naphtha (petroleum), light aromatic | 280 to 470 | 536 to 878 |           |
| 2-Methoxy-1-methylethyl acetate             | 333        | 631.4      | DIN 51794 |

Decomposition temperature : Not available.pH : Not applicable.Viscosity : Not available.

Solubility(ies) :

Not available.

Solubility in water : Not available.

Partition coefficient: n-octanol/ : Not applicable.

water

Vapour pressure

|                      | Va    | Vapour Pressure at 20°C |                |       | apour pres | ssure at 50°C |
|----------------------|-------|-------------------------|----------------|-------|------------|---------------|
| Ingredient name      | mm Hg | kPa                     | Method         | mm Hg | kPa        | Method        |
| Methylisobutylketone | 15.75 | 2.1                     |                |       |            |               |
| iso-butanol          | <12   | <1.6                    | DIN EN 13016-2 |       |            |               |

Relative density : Not available.

Density : 1 g/cm³

Vapour density : Not available.

Explosive properties : Not available.

Oxidising properties : Not available.

**Particle characteristics** 

Median particle size : Not applicable.

# **SECTION 10: Stability and reactivity**

10.1 Reactivity : No specific test data related to reactivity available for this product or its ingredients.

**10.2 Chemical stability** : The product is stable.

10.3 Possibility of hazardous reactions

: Under normal conditions of storage and use, hazardous reactions will not occur.

**10.4 Conditions to avoid** : Avoid all possible sources of ignition (spark or flame). Do not pressurise, cut, weld,

braze, solder, drill, grind or expose containers to heat or sources of ignition.

10.5 Incompatible materials : Reactive or incompatible with the following materials:

oxidising materials

**10.6 Hazardous** : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Date of issue/Date of revision: 10/08/2022Date of previous issue: No previous validationVersion: 111/20INERTA 50 VARNISHLabel No :38447

# **SECTION 11: Toxicological information**

# 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

## **Acute toxicity**

| Product/ingredient name     | Result                    | Species | Dose                    | Exposure |
|-----------------------------|---------------------------|---------|-------------------------|----------|
| Solvent naphtha             | LD50 Oral                 | Rat     | 8400 mg/kg              | -        |
| (petroleum), light aromatic |                           |         |                         |          |
| iso-butanol                 | LC50 Inhalation Vapour    | Rat     | 19200 mg/m <sup>3</sup> | 4 hours  |
|                             | LD50 Dermal               | Rabbit  | 3400 mg/kg              | -        |
|                             | LD50 Oral                 | Rat     | 2460 mg/kg              | -        |
| Xylene                      | LC50 Inhalation Vapour    | Rat     | 21.7 mg/l               | 4 hours  |
|                             | LD50 Oral                 | Rat     | 4300 mg/kg              | -        |
| Methylisobutylketone        | LD50 Oral                 | Rat     | 2080 mg/kg              | -        |
| Cyclohexanone               | LC50 Inhalation Gas.      | Rat     | 8000 ppm                | 4 hours  |
|                             | LD50 Oral                 | Rat     | 1800 mg/kg              | -        |
| 2-Methoxy-1-methylethyl     | LD50 Dermal               | Rabbit  | >5 g/kg                 | -        |
| acetate                     |                           |         |                         |          |
|                             | LD50 Oral                 | Rat     | 8532 mg/kg              | -        |
| Ethylbenzene                | LC50 Inhalation Dusts and | Rat     | 29000 mg/l              | 4 hours  |
|                             | mists                     |         |                         |          |
|                             | LD50 Dermal               | Rabbit  | 15400 mg/kg             | -        |
|                             | LD50 Oral                 | Rat     | 3500 mg/kg              | -        |
| Urea-formaldehyde-polymer   | LD50 Dermal               | Rabbit  | >5 g/kg                 | -        |
|                             | LD50 Oral                 | Rat     | >5 g/kg                 | -        |
| Oxirane, mono[              | LD50 Oral                 | Rat     | 17100 mg/kg             | -        |
| (C12-14-alkyloxy)methyl]    |                           |         |                         |          |
| derivs.                     |                           |         |                         |          |

# Conclusion/Summary

: Based on available data, the classification criteria are not met.

# **Acute toxicity estimates**

| Route              | ATE value                                 |
|--------------------|-------------------------------------------|
| Inhalation (gases) | 8622.28 mg/kg<br>222752 ppm<br>50.61 mg/l |

# **Irritation/Corrosion**

| Product/ingredient name             | Result                   | Species | Score | Exposure         | Observation |
|-------------------------------------|--------------------------|---------|-------|------------------|-------------|
| Solvent naphtha (petroleum),        | Eyes - Mild irritant     | Rabbit  | -     | 24 hours 100     | -           |
| light aromatic                      |                          |         |       | uL               |             |
| Xylene                              | Eyes - Mild irritant     | Rabbit  | -     | 87 mg            | -           |
|                                     | Eyes - Severe irritant   | Rabbit  | -     | 24 hours 5       | -           |
|                                     |                          |         |       | mg               |             |
|                                     | Skin - Mild irritant     | Rat     | -     | 8 hours 60 uL    | -           |
|                                     | Skin - Moderate irritant | Rabbit  | -     | 100 %            | -           |
|                                     | Skin - Moderate irritant | Rabbit  | -     | 24 hours 500     | -           |
|                                     |                          |         |       | mg               |             |
| Methylisobutylketone                | Eyes - Moderate irritant | Rabbit  | -     | 24 hours 100     | -           |
|                                     |                          |         |       | uL               |             |
|                                     | Eyes - Severe irritant   | Rabbit  | -     | 40 mg            | -           |
|                                     | Skin - Mild irritant     | Rabbit  | -     | 24 hours 500     | -           |
|                                     |                          |         |       | mg               |             |
| Cyclohexanone                       | Eyes - Severe irritant   | Rabbit  | -     | 20 mg            | -           |
|                                     | Eyes - Severe irritant   | Rabbit  | -     | 24 hours 250     | -           |
|                                     | China Milal innit and    | 1.1     |       | ug               |             |
|                                     | Skin - Mild irritant     | Human   | -     | 48 hours 50<br>% | -           |
|                                     | Skin - Mild irritant     | Rabbit  |       | 500 mg           |             |
| Ethylbenzene                        | Eyes - Severe irritant   | Rabbit  | -     | 500 mg           | -           |
| Luiyiberizerie                      | Skin - Mild irritant     | Rabbit  | _     | 24 hours 15      | _           |
|                                     |                          | Nabbit  | -     | mg               | _           |
| Urea-formaldehyde-polymer           | Eyes - Severe irritant   | Rabbit  | _     | 24 hours 100     | _           |
| Crea formalderiyae polymer          |                          | Tabbit  |       | uL               |             |
| Oxirane, mono[                      | Skin - Moderate irritant | Rabbit  | _     | 24 hours 500     | _           |
| (C12-14-alkyloxy)methyl]            |                          |         |       | uL               |             |
| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |                          |         |       |                  |             |

Date of issue/Date of revision: 10/08/2022Date of previous issue: No previous validationVersion: 112/20INERTA 50 VARNISHLabel No :38447

# **SECTION 11: Toxicological information**

derivs.

Conclusion/Summary

**Sensitisation** 

: Causes skin irritation.

**Conclusion/Summary** 

**Mutagenicity** 

**Conclusion/Summary** 

: Based on available data, the classification criteria are not met.

**Carcinogenicity** 

: Suspected of causing cancer. Risk of cancer depends on duration and level of **Conclusion/Summary** 

exposure.

**Reproductive toxicity** 

**Conclusion/Summary** 

: Based on available data, the classification criteria are not met.

**Teratogenicity** 

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

: May cause an allergic skin reaction.

## Specific target organ toxicity (single exposure)

| Product/ingredient name                     | Category   | Route of exposure | Target organs                |
|---------------------------------------------|------------|-------------------|------------------------------|
| Solvent naphtha (petroleum), light aromatic | Category 3 | -                 | Respiratory tract irritation |
|                                             | Category 3 |                   | Narcotic effects             |
| iso-butanol                                 | Category 3 | -                 | Respiratory tract irritation |
|                                             | Category 3 |                   | Narcotic effects             |
| Xylene                                      | Category 3 | -                 | Respiratory tract irritation |
| Methylisobutylketone                        | Category 3 | -                 | Narcotic effects             |
| 2-Methoxy-1-methylethyl acetate             | Category 3 | -                 | Narcotic effects             |

### Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category   | Route of exposure                 | Target organs  |
|-------------------------|------------|-----------------------------------|----------------|
| Xylene                  | Category 2 | oral, inhalation oral, inhalation | -              |
| Ethylbenzene            | Category 2 |                                   | hearing organs |

# **Aspiration hazard**

| Product/ingredient name                                               | Result                                                                                       |
|-----------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Solvent naphtha (petroleum), light aromatic<br>Xylene<br>Ethylbenzene | ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 |

Information on likely routes

of exposure

: Not available.

Potential acute health effects

**Eye contact** 

: Causes serious eye damage.

Inhalation

: Can cause central nervous system (CNS) depression. May cause drowsiness or

dizziness. May cause respiratory irritation.

**Skin contact** 

: Causes skin irritation. May cause an allergic skin reaction.

Ingestion

: Can cause central nervous system (CNS) depression.

# Symptoms related to the physical, chemical and toxicological characteristics

**Eye contact** 

: Adverse symptoms may include the following:

pain watering redness

Date of issue/Date of revision : 10/08/2022 Version:1 13/20 Date of previous issue : No previous validation

**INERTA 50 VARNISH Label No: 38447** 

# **SECTION 11: Toxicological information**

**Inhalation** : Adverse symptoms may include the following:

respiratory tract irritation

coughing

nausea or vomiting

headache

drowsiness/fatigue dizziness/vertigo unconsciousness

**Skin contact**: Adverse symptoms may include the following:

pain or irritation

redness

blistering may occur

Ingestion : Adverse symptoms may include the following:

stomach pains

## Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Short term exposure** 

**Potential immediate** 

: Not available.

effects

Potential delayed effects : Not available.

**Long term exposure** 

**Potential immediate** 

: Not available.

effects

Potential delayed effects : Not available.

Potential chronic health effects

Not available.

Conclusion/Summary : Not available.

General: May cause damage to organs through prolonged or repeated exposure. Once

sensitized, a severe allergic reaction may occur when subsequently exposed to very

low levels.

Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of

exposure.

Mutagenicity : No known significant effects or critical hazards.Reproductive toxicity : No known significant effects or critical hazards.

#### 11.2 Information on other hazards

### 11.2.1 Endocrine disrupting properties

Not available.

### 11.2.2 Other information

Not available.

# **SECTION 12: Ecological information**

## 12.1 Toxicity

| Product/ingredient name                     | Result                              | Species                                | Exposure |
|---------------------------------------------|-------------------------------------|----------------------------------------|----------|
| Solvent naphtha (petroleum), light aromatic | Acute EC50 3.2 mg/l                 | Daphnia                                | 48 hours |
|                                             | Acute LC50 9.2 mg/l                 | Fish                                   | 96 hours |
| iso-butanol                                 | Acute LC50 600 mg/l Marine water    | Crustaceans - Artemia salina           | 48 hours |
|                                             | Acute LC50 1030000 μg/l Fresh water | Daphnia - Daphnia magna -<br>Neonate   | 48 hours |
|                                             | Acute LC50 1330000 µg/l Fresh water | Fish - Oncorhynchus mykiss             | 96 hours |
| Methylisobutylketone                        | Acute LC50 505000 µg/l Fresh water  | Fish - Pimephales promelas             | 96 hours |
| ,                                           | Chronic NOEC 78 mg/l Fresh water    | Daphnia - Daphnia magna                | 21 days  |
|                                             | Chronic NOEC 168 mg/l Fresh water   | Fish - Pimephales promelas -<br>Embryo | 33 days  |
| Cyclohexanone                               | Acute EC50 32.9 mg/l Fresh water    | Algae - Chlamydomonas                  | 72 hours |

Date of issue/Date of revision: 10/08/2022Date of previous issue: No previous validationVersion: 114/20INERTA 50 VARNISHLabel No :38447

# **SECTION 12: Ecological information**

|  | Acute LC50 527000 μg/l Fresh water<br>Chronic EC10 3.56 mg/l Fresh water | reinhardtii - Exponential growth<br>phase<br>Fish - Pimephales promelas<br>Algae - Chlamydomonas<br>reinhardtii - Exponential growth<br>phase | 96 hours<br>72 hours |
|--|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
|--|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|----------------------|

**Conclusion/Summary** 

: Harmful to aquatic life with long lasting effects.

#### 12.2 Persistence and degradability

| Product/ingredient name | Test | Result                   | Dose | Inoculum |
|-------------------------|------|--------------------------|------|----------|
| iso-butanol             | -    | 74 % - Readily - 28 days | -    | -        |

**Conclusion/Summary**: This product has not been tested for biodegradation.

| Product/ingredient name | Aquatic half-life | Photolysis | Biodegradability |
|-------------------------|-------------------|------------|------------------|
| iso-butanol             | -                 | -          | Readily          |

# 12.3 Bioaccumulative potential

| Product/ingredient name                               | LogPow | BCF         | Potential |
|-------------------------------------------------------|--------|-------------|-----------|
| Solvent naphtha (petroleum), light aromatic           | -      | 10 to 2500  | high      |
| iso-butanol                                           | 1      | -           | low       |
| Xylene                                                | 3.12   | 8.1 to 25.9 | low       |
| Methylisobutylketone                                  | 1.9    | -           | low       |
| Cyclohexanone                                         | 0.86   | -           | low       |
| 2-Methoxy-1-methylethyl acetate                       | 1.2    | -           | low       |
| Ethylbenzene                                          | 3.6    | -           | low       |
| Oxirane, mono[<br>(C12-14-alkyloxy)methyl]<br>derivs. | 3.77   | 160 to 263  | low       |

### 12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Male: Ital

Mobility : Not available.

### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

### 12.6 Endocrine disrupting properties

Not available.

#### 12.7 Other adverse effects

No known significant effects or critical hazards.

# **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

### **Product**

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Date of issue/Date of revision: 10/08/2022Date of previous issue: No previous validationVersion: 115/20INERTA 50 VARNISHLabel No :38447

# SECTION 13: Disposal considerations

: 080111\*, 200127\*

**Hazardous waste** 

European waste catalogue (EWC) : The classification of the product may meet the criteria for a hazardous waste.

**Packaging** 

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

**Special precautions** 

: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

# **SECTION 14: Transport information**

|                                    | ADR/RID | ADN    | IMDG   | IATA   |
|------------------------------------|---------|--------|--------|--------|
| 14.1 UN number or ID number        | UN1263  | UN1263 | UN1263 | UN1263 |
| 14.2 UN proper shipping name       | PAINT   | PAINT  | PAINT  | Paint  |
| 14.3 Transport<br>hazard class(es) | 3       | 3      | 3      | 3      |
| 14.4 Packing group                 | III     | 111    | III    | III    |
| 14.5<br>Environmental<br>hazards   | No.     | No.    | No.    | No.    |

### **Additional information**

ADR/RID

: <u>Viscous liquid exception</u> This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.2.3.1.5.1. Tunnel code (D/E)

**ADN** 

: Viscous liquid exception This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.2.3.1.5.1.

**IMDG** 

: <u>Viscous liquid exception</u> This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.3.2.5.

user

14.6 Special precautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Maritime transport in bulk according to IMO instruments

: Not relevant/applicable due to nature of the product.

# **SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

**Annex XIV** 

None of the components are listed.

Date of issue/Date of revision 16/20 : 10/08/2022 Date of previous issue : No previous validation Version :1 **INERTA 50 VARNISH Label No: 38447** 

# **SECTION 15: Regulatory information**

#### Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions : Not applicable.

on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

### Other EU regulations

**Industrial emissions** : Not listed

(integrated pollution prevention and control) -

**Air** 

**Industrial emissions** : Not listed

(integrated pollution prevention and control) -

Water

## Ozone depleting substances (1005/2009/EU)

Not listed.

### Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

### **Persistent Organic Pollutants**

Not listed.

#### **Seveso Directive**

This product is controlled under the Seveso Directive.

### **Danger criteria**

Category

P5c

#### **International regulations**

# Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

### **Montreal Protocol**

Not listed.

### **Stockholm Convention on Persistent Organic Pollutants**

Not listed.

# Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

# **UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

15.2 Chemical safety assessment

: This product contains substances for which Chemical Safety Assessments are still required.

Date of issue/Date of revision : 10/08/2022 Date of previous issue Version:1 17/20 : No previous validation **Label No: 38447** 

# **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

Abbreviations and acronyms

: ATE = Acute Toxicity Estimate

CLP = Classification, Labelling and Packaging Regulation (EC) No.

1272/2008

DMEL = Derived Minimal Effect Level
DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

| Classification          | Justification         |
|-------------------------|-----------------------|
| Flam. Liq. 3, H226      | On basis of test data |
| Skin Irrit. 2, H315     | Calculation method    |
| Eye Dam. 1, H318        | Calculation method    |
| Skin Sens. 1, H317      | Calculation method    |
| Carc. 2, H351           | Calculation method    |
| STOT SE 3, H335         | Calculation method    |
| STOT SE 3, H336         | Calculation method    |
| STOT RE 2, H373         | Calculation method    |
| Aquatic Chronic 3, H412 | Calculation method    |

### Full text of abbreviated H statements

| H225   | Highly flammable liquid and vapour.                                |
|--------|--------------------------------------------------------------------|
| H226   | Flammable liquid and vapour.                                       |
| H304   | May be fatal if swallowed and enters airways.                      |
| H312   | Harmful in contact with skin.                                      |
| H315   | Causes skin irritation.                                            |
| H317   | May cause an allergic skin reaction.                               |
| H318   | Causes serious eye damage.                                         |
| H319   | Causes serious eye irritation.                                     |
| H332   | Harmful if inhaled.                                                |
| H335   | May cause respiratory irritation.                                  |
| H336   | May cause drowsiness or dizziness.                                 |
| H351   | Suspected of causing cancer.                                       |
| H373   | May cause damage to organs through prolonged or repeated exposure. |
| H411   | Toxic to aquatic life with long lasting effects.                   |
| H412   | Harmful to aquatic life with long lasting effects.                 |
| H413   | May cause long lasting harmful effects to aquatic life.            |
| EUH066 | Repeated exposure may cause skin dryness or cracking.              |

# Full text of classifications [CLP/GHS]

| Acute Tox. 4      | ACUTE TOXICITY - Category 4                                     |
|-------------------|-----------------------------------------------------------------|
| Aquatic Chronic 2 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2                 |
| Aquatic Chronic 3 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3                 |
| Aquatic Chronic 4 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 4                 |
| Asp. Tox. 1       | ASPIRATION HAZARD - Category 1                                  |
| Carc. 2           | CARCINOGENICITY - Category 2                                    |
| Eye Dam. 1        | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1                  |
| Eye Irrit. 2      | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2                  |
| Flam. Liq. 2      | FLAMMABLE LIQUIDS - Category 2                                  |
| Flam. Liq. 3      | FLAMMABLE LIQUIDS - Category 3                                  |
| Skin Irrit. 2     | SKIN CORROSION/IRRITATION - Category 2                          |
| Skin Sens. 1      | SKIN SENSITISATION - Category 1                                 |
| STOT RE 2         | SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2 |
| STOT SE 3         | SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3   |

Date of issue/ Date of

revision

: 10/08/2022

Date of previous issue : No previous validation

Date of issue/Date of revision: 10/08/2022Date of previous issue: No previous validationVersion: 118/20INERTA 50 VARNISHLabel No :38447

# **SECTION 16: Other information**

Version

## **Notice to reader**

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Version :1 Date of issue/Date of revision : 10/08/2022 Date of previous issue : No previous validation 19/20 **Label No: 38447** 

Date of issue/Date of revision: 10/08/2022Date of previous issue: No previous validationVersion: 120/20INERTA 50 VARNISHLabel No :38447